DOP2023000155A - Tratamiento y terapia de mantenimiento para el cáncer de vejiga con gemcitabina - Google Patents

Tratamiento y terapia de mantenimiento para el cáncer de vejiga con gemcitabina

Info

Publication number
DOP2023000155A
DOP2023000155A DO2023000155A DO2023000155A DOP2023000155A DO P2023000155 A DOP2023000155 A DO P2023000155A DO 2023000155 A DO2023000155 A DO 2023000155A DO 2023000155 A DO2023000155 A DO 2023000155A DO P2023000155 A DOP2023000155 A DO P2023000155A
Authority
DO
Dominican Republic
Prior art keywords
gemcitabine
treatment
maintenance therapy
bladder cancer
therapy
Prior art date
Application number
DO2023000155A
Other languages
English (en)
Inventor
Cutie Christopher
Giessing Dennis
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of DOP2023000155A publication Critical patent/DOP2023000155A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan métodos para tratar carcinomas uroteliales del tracto inferior que comprenden administrar gemcitabina continuamente y localmente a la vejiga de un individuo en una terapia de inducción y/o terapia de mantenimiento.
DO2023000155A 2017-11-08 2023-08-04 Tratamiento y terapia de mantenimiento para el cáncer de vejiga con gemcitabina DOP2023000155A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762583394P 2017-11-08 2017-11-08
PCT/US2018/059698 WO2019094517A1 (en) 2017-11-08 2018-11-07 Methods of treatment and maintenance therapy for bladder cancer using gemcitabine

Publications (1)

Publication Number Publication Date
DOP2023000155A true DOP2023000155A (es) 2023-12-29

Family

ID=66439297

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2023000155A DOP2023000155A (es) 2017-11-08 2023-08-04 Tratamiento y terapia de mantenimiento para el cáncer de vejiga con gemcitabina

Country Status (18)

Country Link
US (3) US10792297B2 (es)
EP (1) EP3706763A4 (es)
JP (2) JP2021502347A (es)
KR (1) KR20200085822A (es)
CN (1) CN111787926A (es)
AU (1) AU2018366106A1 (es)
BR (1) BR112020008700A2 (es)
CA (1) CA3081839A1 (es)
DO (1) DOP2023000155A (es)
EA (1) EA202091143A1 (es)
IL (2) IL302714A (es)
JO (1) JOP20200124A1 (es)
MA (1) MA50581A (es)
MX (2) MX2020004771A (es)
PE (1) PE20210041A1 (es)
PH (1) PH12020550587A1 (es)
SG (1) SG11202003950WA (es)
WO (1) WO2019094517A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3658153A4 (en) 2017-07-25 2021-04-21 TARIS Biomedical LLC METHOD OF TREATMENT OF TUMOR METASTASIS
WO2024092159A1 (en) * 2022-10-28 2024-05-02 Taris Biomedical Llc Methods of treating bladder cancer with gemcitabine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101710148B1 (ko) 2009-06-26 2017-02-27 타리스 바이오메디컬 엘엘씨 이식가능한 약물전달 디바이스에 사용되기 위한 고체 약물 정제
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
AU2010339821B2 (en) 2009-12-17 2015-02-19 Taris Biomedical Llc Implantable device with intravesical tolerability and methods of treatment
BR112012030699A2 (pt) 2010-06-02 2016-09-13 Abraxis Bioscience Llc métodos para tratar câncer de bexiga
EP2600800B1 (en) 2010-08-05 2020-09-30 TARIS Biomedical LLC Ureteral stent drug delivery device and kit
JP6043730B2 (ja) 2011-02-04 2016-12-14 タリス バイオメディカル エルエルシー 低溶解性薬物の制御された放出のための植込み型装置
JP6639228B2 (ja) * 2012-03-29 2020-02-05 アルター・バイオサイエンス・コーポレーション 新生物を治療するための方法
AU2013308464B2 (en) 2012-08-31 2018-02-01 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin
SG11201501483XA (en) 2012-08-31 2015-03-30 Taris Biomedical Llc Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine
US10137287B2 (en) 2013-03-05 2018-11-27 Taris Biomedical Llc Drug delivery devices and methods for controlled drug release through device orifice
MX2021001657A (es) 2013-03-15 2022-04-21 Taris Biomedical Llc Dispositivos de administración de medicamentos y métodos para administración de medicamentos.
MX2015012367A (es) 2013-03-15 2016-05-31 Taris Biomedical Llc Dispositivos de suministro de farmacos con un componente permeable al farmaco y metodos.
DE102013103986A1 (de) 2013-04-19 2014-10-23 B. Braun Avitum Ag Rezirkulationsvorrichtung eines extrakorporalen Blutbehandlungsgeräts
AU2014309012B2 (en) 2013-08-19 2019-03-14 Taris Biomedical Llc Multi-unit drug delivery devices and methods
RS63675B1 (sr) 2014-03-06 2022-11-30 Taris Biomedical Llc Sistemi za isporuku leka i metode za lečenje raka bešike gemcitabinom
KR102391761B1 (ko) 2014-06-26 2022-04-27 타리스 바이오메디컬 엘엘씨 탄성 폴리머-약물 매트릭스 시스템을 포함하는 방광내 약물 전달 장치 및 방법
JP7425534B2 (ja) 2015-04-23 2024-01-31 タリス バイオメディカル エルエルシー 薬物透過性構成要素を有する薬物送達デバイス及び方法
RU2022100624A (ru) 2016-05-06 2022-02-09 ТЭРИС БАЙОМЕДИКАЛ ЭлЭлСи Способ лечения рака уротелия нижних путей
EP3658153A4 (en) 2017-07-25 2021-04-21 TARIS Biomedical LLC METHOD OF TREATMENT OF TUMOR METASTASIS
CN112839653A (zh) 2018-08-01 2021-05-25 塔里斯生物医药公司 使用曲司氯铵治疗膀胱过度活动症的方法

Also Published As

Publication number Publication date
KR20200085822A (ko) 2020-07-15
US10792297B2 (en) 2020-10-06
CA3081839A1 (en) 2019-05-16
MX2023007680A (es) 2023-07-07
EA202091143A1 (ru) 2020-07-30
IL274343A (en) 2020-06-30
BR112020008700A2 (pt) 2020-10-27
MX2020004771A (es) 2020-10-19
IL274343B1 (en) 2023-06-01
JP2024009888A (ja) 2024-01-23
US20190175637A1 (en) 2019-06-13
IL302714A (en) 2023-07-01
US20230321129A1 (en) 2023-10-12
MA50581A (fr) 2020-09-16
SG11202003950WA (en) 2020-05-28
JP2021502347A (ja) 2021-01-28
AU2018366106A1 (en) 2020-05-14
CN111787926A (zh) 2020-10-16
EP3706763A1 (en) 2020-09-16
WO2019094517A1 (en) 2019-05-16
IL274343B2 (en) 2023-10-01
PE20210041A1 (es) 2021-01-08
JOP20200124A1 (ar) 2020-05-20
US20210085705A1 (en) 2021-03-25
EP3706763A4 (en) 2021-08-11
PH12020550587A1 (en) 2021-04-26

Similar Documents

Publication Publication Date Title
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
DOP2023000155A (es) Tratamiento y terapia de mantenimiento para el cáncer de vejiga con gemcitabina
CO2020009091A2 (es) Exosomas para inmunooncología y terapia antiinflamatoria
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CO2017007662A2 (es) Terapias de combinación para el tratamiento de cánceres
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
ECSP17073743A (es) Moduladores de k-ras
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
BR112018013731A2 (pt) combinações anti-egfr para o tratamento de tumores
PE20171138A1 (es) Modulacion inmunitaria
EA201790737A1 (ru) Комбинированная терапия
AR104664A1 (es) Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6)
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
MX2022008868A (es) Tratamiento del cancer con tg02.
BR112017016772A2 (pt) bactérias probióticas recombinantes para uso no tratamento de uma disfunção inflamatória da pele e método para tratá-la
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
ECSP17014159A (es) Terapia adjuntiva con 25-hidroxi vitamina d
DOP2019000019A (es) Metodos para tratar el cancer de prostata
AR112102A1 (es) Tinostamustina para utilizar en el tratamiento de cáncer de ovario
CO2020001107A2 (es) Moduladores terapéuticos del modo inverso de la atp sintasa
CL2020001888A1 (es) Terapia de combinación para tratar o prevenir el cáncer.
CL2019000846A1 (es) Proteína terapéutica.
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
CL2023003090A1 (es) Combinaciones de composiciones terapéuticas y usos para tratar cánceres